• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Provectus gains patent allowance for PH-10 in the EU

Knoxville, Tenn. - Provectus Pharmaceuticals has received allowance of its patent application in the European Union to cover PH-10, as well as other related agents and their use, Businesswire reports.

Knoxville, Tenn.

- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.

The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.